ICHG2024 International Colloquium on Hyperemesis Gravidarum 2024 Abstracts (22 abstracts)
1Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.; 2Brandenburg Medical School, University Clinic for Psychiatry and Psychotherapy, Immanuel Klinik Rüdersdorf, Seebad 82/83, 15562, Rüdersdorf bei Berlin, Germany.; 3Department of Chemistry, Umeå University, 901 87 Umeå, Sweden.; 4Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; 5Department of Obstetrics and Gynecology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.; 6Section for Experimental Tumor Immunology, Department of Obstetrics and Gynecology, University Hospital of Würzburg, Würzburg, Germany.; 7Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Email Address: [email protected] (S Koskinen Edblom)*, [email protected] (B Haack), [email protected] (M Nording), [email protected] (M Bixo), [email protected] (E Vanky), [email protected] (J Wischhusen), [email protected] (M Fejzo), [email protected] (M-T Vinnars)
Polycystic ovary syndrome (PCOS) may be associated with lower pre-pregnancy GDF-15 levels which we hypothesize could increase their risk for hyperemesis gravidarum (HG). Our objectives were to study the potential association between HG and PCOS, and to measure GDF-15 in pregnant women with PCOS. A cohort study including 793 women with HG, and 571 controls with self-reported PCOS; and 57 pregnant women with PCOS, and systematically registered nausea, antiemetic use, and sick leave due to HG. GDF-15 was measured in the PCOS cohort (n = 57) and in 13 healthy pregnant controls. We used t-test and odds ratio with logistic regression. We found increased odds for PCOS diagnosis in the HG cohort, (OR 2.0, 95% CI:1.1-3.5, P = 0.02). In the PCOS cohort (n = 57), 58 % reported nausea, and 12% were on HG treatment/sick leave. In early pregnancy, the median (IQR) GDF-15 was 9.2 (7.4-11.6) ng/ml in women with PCOS, compared to 10.5 (9.1-16.8) ng/ml in controls (P = 0.036). No difference was seen between PCOS on HG treatment/sick leave, compared to the remaining women with PCOS (P = 0.16). At mid-pregnancy (gw19), the median (IQR) was 78.2 (59.7-95.8) ng/ml in PCOS with nausea, compared to 55.9 (46.3-73.3) ng/ml in the remaining (P = 0.019). In late pregnancy (gw36), the median (IQR) GDF-15 was 92.2 (59.2-106.2) ng/ml in those PCOS with early pregnancy HG treatment/sick leave, compared to 58.7 (47.0-78.0) ng/ml in the remaining women with PCOS (P = 0.034). In conclusion, women with PCOS have an increased risk for HG. High increase in GDF-15 was associated with HG.
Keywords: GDF-15, polycystic ovary syndrome, PCOS, hyperemesis gravidarum, HG
References
12 de Zegher F, Díaz M, Villarroya J, Cairó M, López-Bermejo A, Villarroya F, Ibáñez L. The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat. Sci ReP. 2021 Mar 29;11(1):7018. doi: 10.1038/s41598-021-86317-9. Erratum in: Sci Rep. 2021 Oct 8;11(1):20412. doi: 10.1038/s41598-021-99918-1.
22 Fejzo M, Rocha N, Cimino I, Lockhart SM, Petry CJ, Kay RG, Burling K, Barker P, George AL, Yasara N, Premawardhena A, Gong S, Cook E, Rimmington D, Rainbow K, Withers DJ, Cortessis V, Mullin PM, MacGibbon KW, Jin E, Kam A, Campbell A, Polasek O, Tzoneva G, Gribble FM, Yeo GSH, Lam BYH, Saudek V, Hughes IA, Ong KK, Perry JRB, Sutton Cole A, Baumgarten M, Welsh P, Sattar N, Smith GCS, Charnock-Jones DS, Coll AP, Meek CL, Mettananda S, Hayward C, Mancuso N, ORahilly S. GDF15 linked to maternal risk of nausea and vomiting during pregnancy. Nature. 2024 Jan;625(7996):760-767. doi: 10.1038/s41586-023-06921-9.